Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Genentech Opens New Bay Area Green Building to House Up to 1,500 Workers

May 22, 2015By Mark Terry, Breaking News Staff On Thursday May 21, Genentech (RHHBY) had a ribbon-cutting ceremony for the opening of Building 35, a 255,000-square-foot that will be the site for the company’s product development and bioinformatics units. Genentech did not respond to a request for an interview in time for deadline. Genentech […]

Read More »

Amgen ends partnership with AstraZeneca on psoriasis drug

Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.   Amgen said such safety concerns would likely result in a restrictive label that could limit the number of patients using the late-stage experimental drug, brodalumab. The company […]

Read More »

Mylan CEO Says Pfizer Should Come Calling, As Next Big Deal Speculation Swirls

The speculation surrounding which big deal Pfizer Inc. (PFE) is likely to do in this white hot market reached another level Friday, after Mylan Executive Chairman Robert Coury said he viewed Pittsburgh, Penn.-based Mylan Inc. as a good fit for Pfizer if his company is successful in buying smaller generic drugmaker Perrigo Company (PRGO). Pfizer […]

Read More »

As Market Roars, Gilead Looking for Value-Added Deals, Says CFO

Booming biotech Gilead Sciences, Inc. (GILD) is looking for “value-added” deals as opposed to ones that create synergies, the company’s chief financial officer told attendees at the UBS 2015 Global Healthcare Conference in New York this week, renewing speculation that Gilead may be looking to buy a large pharmaceutical operation with an existing research and […]

Read More »

Strides Arcolab Limited Ponies Up $299.90 Million for Aspen Pharmacare’s Drug Brands

Indian drugmaker Strides Arcolab Limited is widening its portfolio of generics, saying Thursday it will buy Aspen Pharmacare Ltd.’s Australian unit for around $300 million. Strides said the deal is slated to close by the end of the second quarter. Aspen is a South African pharmaceutical company and the sale today pushes Strides and its […]

Read More »

Stock Soars as bluebird bio Gives Sneak Peak at Promising Sickle Cell Data

bluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association Presenting new and updated data from HGB-205 study in beta-thalassemia major and severe sickle cell disease, including first patient with sickle cell disease ever treated with gene therapy   Company to host investor call on Monday, June 15, 2015 at 8:00 […]

Read More »

J&J to submit at least 10 medicines for approval by 2019

U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of the experimental drug daratumumab for […]

Read More »

Novo Nordisk rejects Baxter patent claim over Novoeight

Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder hemophilia, the Danish company said on Wednesday. Baxter had said Novo Nordisk’s newly launched hemophilia drug Novoeight infringed some of its patents, prompting an investigation from the U.S. International Trade […]

Read More »

Lpath to cut jobs as eye drug fails mid-stage study; shares fall

Drug developer Lpath Inc said it would cut jobs and costs after its experimental eye drug failed a mid-stage study in patients with wet age-related macular degeneration, a leading cause of blindness in the elderly. The biotechnology company’s shares fell nearly 71 percent to $0.50 in premarket trading on Wednesday. Lpath, which had about 25 […]

Read More »

Orexigen CEO Pledged To Keep Data Secret, But Not From Himself

In an interview two years ago, Orexigen Chief Executive Mike Narachi understood that data from the largest clinical trial of his company’s weight loss drug Contrave were to be kept secret except for “a small team” that would use it to file for approval with the Food and Drug Administration. However, Narachi differed from CEOs […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom